文献速递脊柱关节炎其他结缔组织病

Ixekizumab治疗活动性银屑病型及附着点炎相关型幼年特发性关节炎:COSPIRIT-JIA试验

Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.
PubMed 文献 · Lancet Rheumatol · 2026-03-02

COSPIRIT-JIA是一项多中心、开放标签、3期试验,纳入101例活动性附着点炎相关关节炎或幼年银屑病关节炎患儿,评估Ixekizumab的疗效与安全性,并设随机阿达木单抗参考组。第16周时,生物制剂初治患者JIA-ACR30应答率为90%,经治患者为86%;不良事件多为轻中度,无严重事件。

要点

  • Ixekizumab在生物制剂初治和经治患儿中均显示较高JIA-ACR30应答率。
  • 安全性与其他适应症一致,不良事件多为轻中度,无严重事件。
  • 研究设阿达木单抗随机参考组,但主要疗效分析针对Ixekizumab组。

核心结论

  • Ixekizumab对适合生物制剂治疗的附着点炎相关关节炎和幼年银屑病关节炎患儿有效且耐受性良好。

研究设计与样本

  • 多中心、开放标签、3期研究,纳入101例患儿(Ixekizumab组81例,阿达木单抗组20例),初始40例生物制剂初治者按1:1随机分配,其余61例分配至Ixekizumab组。

主要发现

  • Ixekizumab组治疗中出现的不良事件多为轻度(46%)或中度(36%),无严重治疗中出现的不良事件报告。

关键数值与推荐

  • 主要终点为第16周JIA-ACR30应答率,定义为6个核心结局变量中至少3个较基线改善≥30%,且其他变量中不超过1个恶化>30%。
  • Ixekizumab按体重给药:起始剂量40-160 mg,随后20-80 mg每4周一次;阿达木单抗20-40 mg每2周一次。

临床怎么用

  • 对于适合生物制剂治疗的附着点炎相关关节炎或幼年银屑病关节炎患儿,Ixekizumab可作为治疗选择。

局限性

  • 开放标签设计,主要疗效分析无对照比较,阿达木单抗组样本量较小。
  • 有幼年特发性关节炎亲身经历者未参与研究设计或实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Juvenile psoriatic arthritis and enthesitis-related arthritis are two categories of juvenile idiopathic arthritis (JIA). Despite available treatments including non-steroidal anti-inflammatory drugs, glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), and biological DMARDs, a substantial proportion of people do not adequately respond to treatment or do not have long-lasting clinical remission. The aim of this trial was to show the efficacy and safety of ixekizumab in children with active enthesitis-related arthritis and juvenile psoriatic arthritis. METHODS: COSPIRIT-JIA is an ongoing multicentre, open-label, phase 3 study of ixekizumab, with a randomised adalimumab reference group, in children with a diagnosis of enthesitis-related arthritis (aged 6 to <18 years) and juvenile psoriatic arthritis (aged 2 to <18 years). Eligible participants had three or more active peripheral joints (presence of swelling or limited motion with pain or tenderness) and a bodyweight of at least 10 kg. Participants received subcutaneous administration of either ixekizumab or adalimumab using a weight-based dosing regimen (ixekizumab 40-160 mg starting dose then 20-80 mg once every 4 weeks; and adalimumab 20-40 mg once every 2 weeks). The primary endpoint was the percentage of ixekizumab-treated participants meeting the JIA-American College of Rheumatology (ACR) 30 (defined as at least 30% improvement from baseline in three of any six core outcome variables, with no more than one of the other variables worsening by more than 30%) response criteria at week 16. A Bayesian analysis was used to assess JIA-ACR30 response rate at week 16. Safety data were summarised using descriptive statistics for all participants who received at least one dose of either treatment. People with lived experience of JIA were not involved in the design or conduct of this study. The trial was registered with ClinicalTrials.gov, NCT04527380. FINDINGS: The study enrolled 101 patients (ixekizumab n=81, adalimumab n=20) between April 13, 2021, and April 2, 2024, of whom the initial 40 participants naive to biological DMARD treatment were randomly assigned 1:1 to ixekizumab or adalimumab and the additional 61 participants were assigned to ixekizumab. Of the 81 participants who received ixekizumab, 60 were biological DMARD naive (40 with enthesitis-related arthritis and 20 with juvenile psoriatic arthritis) and 21 were biological DMARD experienced (14 with enthesitis-related arthritis and seven with juvenile psoriatic arthritis). The median age of the participants in the ixekizumab group was 14 years (12·0-15·0), of whom 36 (44%) of 81 were female, and 69 (85%) of 81 were White. At week 16, 90% (54 of 60; 95% CI 82·4-97·6) of biological DMARD-naive participants and 86% (18 of 21; 70·7-100·0) of biological DMARD-experienced participants receiving ixekizumab had a JIA-ACR30 response. Treatment-emergent adverse events were mostly mild (46%) or moderate (36%) for the ixekizumab group, with no severe treatment-emergent adverse events reported. The safety profile was consistent with adult psoriatic arthritis or spondyloarthritis and paediatric psoriasis indications. INTERPRETATION: Ixekizumab was well tolerated and effective for the treatment of children with enthesitis-related arthritis and juvenile psoriatic arthritis who are candidates for biological DMARD therapy. FUNDING: Eli Lilly and Company.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ramanan AV, Ruperto N, Foeldvari I, et al. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab. Lancet Rheumatol. 2026. PMID: 41785908. doi:10.1016/S2665-9913(25)00346-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。